Alkermes' schizophrenia drug Aristada gets FDA nod

Date:

The U.S. Food and Drug Administration on Monday approved Alkermes Plc’s longer-acting injectable version of blockbuster schizophrenia pill Abilify, making the treatment available in two doses.

Thank you for reading this post, don't forget to subscribe!

Abilify, developed by Japanese drugmaker Otsuka Pharmaceuticals and sold in the United States by Bristol-Myers Squibb Co, is already facing generic competition.

Alkermes’ injectable version, Aristada, is expected to be launched immediately, the company said in a statement on Monday.

 

Babatunde Akinsola
Babatunde Akinsolahttps://naija247news.com
Babatunde Akinsola is aNaija247news' Southwest editor. He's based in Lagos and writes on the Yoruba Nation political issues, news and investigative reports

Share post:

Subscribe

Popular

More like this
Related

Access Holdings to pay N1.80 as final dividend to shareholder

March 28, 2024. Azonuchechi Chukwu. Access Holdings has revealed plans to...

Police gun down two notorious bandits in Benue

March 28, 2024. Azonuchechi Chukwu. Men of Operation Zenda, a Joint...

Army declares eight wanted in connection with the k!lling of its officers in Okuama

March 28, 2024. Azonuchechi Chukwu. The Nigerian Army has declared eight...

Naira Appreciates Against Dollar at the NAFEM Window

March 28, 2024. Azonuchechi Chukwu. The Naira’s euphoric appreciation against the...
Social Media Auto Publish Powered By : XYZScripts.com

Discover more from Naija247news

Subscribe now to keep reading and get access to the full archive.

Continue reading